Head-to-head · Value Score
Gimme Care vs Lttl
Two GLP-1 deals, scored on the same six factors. Gimme Care lands a Value Score of 91, Lttl a 73. Here's who gives you the honest lower price — and where each one bites back.
Gimme Care
#5 · Grade A · Best Value
Est. first month
$130/mo
Save ~90% vs brand-nameLttl
#176 · Grade C+ · Watch List
Est. first month
From $149/mo (compounded)
Save ~89% vs brand-nameThe verdict
Gimme Care takes it on Value Score, 91 to 73 — an est. $130/mo first month, with no teaser step-up baked in. Lttl isn't out of it: Shoppers who want every commitment tier priced openly, plus a low-dose microdose option.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Gimme Care | Lttl |
|---|---|---|
| Value Score | 91 (A) | 73 (C+) |
| Est. first month | $130/mo | From $149/mo (compounded) |
| Save vs brand-name | ~90% | ~89% |
| Semaglutide | $130/mo | From $149/mo (compounded) |
| Tirzepatide | $163/mo | From $149/mo (compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Gimme Care
Genuinely cheap on both molecules ($130 / $163) with a LegitScript-certified pharmacy and all-50-state reach.
Why it's a deal
- Low flat price on both molecules ($130 sema / $163 tirz)
- LegitScript-certified pharmacy
- Available in all 50 states
The fine print
- No brand-name option — compounded only
- No oral/sublingual form
Lttl
Lttl (pronounced 'little') is a direct-to-consumer telehealth brand offering compounded semaglutide and tirzepatide, a low-dose 'microdose' line, and longevity peptides.
Why it's a deal
- Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
- Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
- States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
- Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
- Oral ODT semaglutide offered for members who want to avoid injections
The fine print
- Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
- The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
- No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
- Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
- Medications cannot be returned or refunded once they ship from the pharmacy
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Gimme Care is ranked on the Gimme Care alternatives board, and the same list for the other side is on alternatives to Lttl.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.